OTCM
HRTDF
, Last price
USD
Name
Heartseed Inc
Chart & performance
P/E
—
P/S
—
EPS
7.43
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
3.03b
+246.44%
Net income
163m
P
CFO
1.08b
0.00%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Heartseed Inc. is a Japan-based company engaged in research and development of regenerative medicine products. The company has established cardiac regenerative medicine, a therapy in which microtissue derived from iPS cells is transplanted into the heart for patients with severe heart failure. Target diseases include dilated cardiomyopathy, old myocardial infarction, and dilated-phase hypertrophic cardiomyopathy.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2025‑12 | 2025‑10 | 2024‑10 | 2023‑10 | 2022‑10 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||